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OBJECTIVES: Personalized medicine is characterized by an increasing number of
tests andpayer scrutiny over their value. Depending on the use of a test, health care
costs and outcomes may change in predictable ways. METHODS: We describe six
uses of tests, matching each with value hypotheses and a generic decision tree
framework thatmay be used to study test cost-effectiveness.Wemake distinctions
between screening (to identify those in a population likely to have or develop a
disease), diagnostic (to diagnose), predictive (to predict response to or toxicity from
a particular treatment, often referred to as a companion diagnostic), prognostic (to
identify patients at risk for a specific outcome, regardless of the choice of treat-
ment), surveillance (for patients with no sign of disease at completion of treatment
to identify those at risk of recurrence), andmonitoring (to detect response to treat-
ment or disease progression) tests. We specify how each test is expected to affect
health care costs and/or outcomes, followed by the nature and direction of the
effects.We also show the importance of properlymodeling the distinction between
these tests. For example, by identifying earlier or more accurately patients at
higher risk, a new screening test may lead to diagnosis at lower levels of disease
severity, resulting (from treatment) in improved life expectancy (LE) and/or quali-
ty-adjusted LE. Also, by identifying patients at lower risk, a new screening testmay
reduce costs associated with unnecessary future testing. Comparatively, we find
that salient elements of a general model structure for a new screening test include
screening compliance and distribution by severity at diagnosis, which are less
pertinent to other test uses. CONCLUSIONS: Testsmay be expected to affect health
care costs and outcomes in predictableways depending on the type of test; we offer
model structures that reflect these distinctions.
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TURNING THE IMPLAUSIBLE TO THE PLAUSIBLE: TOWARDS A BETTER
CONTROL OF OVER THE COUNTER DISPENSING OF ANTIBIOTICS IN EGYPT
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As a developing country, Egypt has long suffered negative outcomes from irrational
drug dispensing practices. This affected health economics adversely and increased
the burden of antibiotic resistance. With limited research data on this specific area
in Egypt, it becomes imperative to guide the researchers to potential adverse ef-
fects of over-the-counter dispensing on antibiotic resistance prevalence. This re-
search aims to define the flaws in antibiotic dispensing in Egypt and its impact on
the access to antibiotics. Spending on pharmaceuticals in Egypt constitutes 34% of
the total health care spending. TheMinistry of Health and Population has enforced
several laws prohibiting over-the-counter dispensing of drugs. However, there is
limited evidence on the effectiveness of those regulations on inappropriate dis-
pensing. Literature review revealed that only one report that dates back to 1998
addressed this area of inquiry. Analysis of 1174 dispensed products in 25 different
districted pharmacies in Alexandria showed that 60% of medications dispensed
were without a prescription or a pharmacist recommendation. Among those prod-
ucts, there were 98 different antibiotic products of which 42% were dispensed
without a prescription. Over all, Egypt suffers a high percentage of over-the-coun-
ter dispensing of drugswith little studies paying attention to this aspect in terms of
antibiotic resistance patterns. Despite enforced laws prohibiting over-the-counter
dispensing of drugs, further interventions are required. More strict laws must ap-
ply to pharmacists who do not complywith the official regulations of drug dispens-
ing. Further studies should inquire into non-optimal dispensing practices. Educa-
tional campaigns for patients to increase their level of awareness are crucial to
decrease wasteful drug spending and ensure approximate containment of newly
emerging antibiotic resistance in the near future.
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BACKGROUND: Investment decisions aremade on the basis of whether a new drug
is expected to meet certain criteria specified in a target product profile (TPP). Sim-
ilarly, such decisions assume a target price, which is used in calculations of return-
on-investment. Assuming a payer-cost-effectiveness threshold, threshold pricing
models are used to estimate themaximumvalue-based price assuming a new drug
achieves its TPP, and to estimate minimum value-based efficacy, safety, and toler-
ability required to support a target price. To assess the effects of uncertainty, one-
way and probabilistic sensitivity analyses may be tailored to apply to threshold
pricing models; however, to assess the risk to attaining a target price if a new drug
were to fail to achieve a particular criterion, it is essential to understand the rela-
tionships among the criteria listed in the TPP.METHODS:Wedescribe an extension
of threshold pricing analysis to include trade-off assessment. For example, a new
drug may be expected to reduce the risk of hospitalization, reduce hospital length
of stay, and reduce mortality, each by a certain amount, the combined achieve-
ment of which supports a particular value-based priced. Using trade-off analysis, it
is possible to estimate the improvement required in one attribute to offset the
failure of the new drug to achieve the expected effect in another attribute. In our
example, trade-off analysismay suggest that if the newdrugwere to fail to produce
an expected 5% mortality reduction, the new drug will need to quadruple the
reduction in hospital length of stay to achieve the same value based price. We
present tabular and graphical depictions of how multiple target attribute levels
may offset each other in a new drug’s ability to achieve a value-based price.
CONCLUSIONS: Trade-off analyses when applied to a threshold-pricingmodel can
make important contributions to value-based product development.
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OBJECTIVES: To discuss the different methods of multi criteria decision analysis
(MCDA) that could be used in health technology assessment (HTA) and their rela-
tive merits. METHODS: The current practice of health technology appraisals is
based on the incremental cost-effectiveness ratio (ICER) i.e. the incremental cost
per quality adjusted life year (QALY) gained by recipients of treatment. Even though
other factors (e.g. severity, life saving, etc) are considered alongwith ICERs, there is
concern that its approach may fail to capture other important sources of value.
MCDA is aimed at supporting decision makers faced with evaluating alternatives
taking into account multiple, and often conflictive, criteria in an explicit manner.
This paper addresses a number of important questions to identify the most appro-
priate MCDAmethod that might be used to support decisionmaking. For example,
what criteria should be incorporated? Whose weights should be used and how to
elicit them? How to incorporate uncertainty into the MCDA process? How do we
consider the value of displaced technologies? What should the ‘basic’ cost-effec-
tiveness threshold be? How do we estimate it? This paper will discuss these ques-
tions, outline and assess methodological issues that would be raised by the use of
MCDA in health technology assessment (HTA). RESULTS: A potential MCDA ap-
proach for HTA is to calculate “weighted” QALYs from the QALY weights which
reflect the broader value of the product’s benefits and compare against the updated
“basic threshold” value. CONCLUSIONS: There are general practical issues that
might arise from using this MCDA approach in the HTA process and further re-
search needs to be performed to address the issues identified in order to ensure the
success of this MCDA technique in the appraisal process.
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Regulatory authorities inmany countries require that societal preferences are used
when health (dis)benefits are reported in terms of quality-adjusted life-years
(QALYs). In the United Kingdom the NICE reference case, as set out in its published
technical guidance, cites EQ-5D as the requisite health-related quality of life
(HrQoL) system and Time Trade-Off (TTO) as the preferred method for eliciting
societal values. This stipulation is simple to assert, but virtually impossible to
justify and/or operationalise in practice. Nevertheless this has been the UK default
position for many years and has established a de facto national “norm”. These
issues, however, are global in nature and common to economic evaluation of
healthcare in all countries. TheUK “preference” for TTO is nomore than that, for no
scientific case has been made for rejecting Standard Gamble (SG), commonly ac-
knowledged to yield systematically different estimates of utility. Both methods
cannot be correct - one (at least) must be in error. It is patently absurd to consider
them as commensurable equivalents in QALY calculations. In principle, a similar
difficulty arises as new value sets are published, as will be the case in respect of the
5-level version of EQ-5D. Cost-utility analysis reported in the literature reveals a
10-fold difference in incremental benefits (change frombaseline)when EQ-5D/HUI/
SF-6D are used to compute QALYs, sufficient to reverse the location of an ICERwith
respect to any threshold. The central issue is that of updating the choice of a
definitive value set for reference case analysis. This paper argues for a decision-
centric approach inwhich a newmetricmay only be adopted if its use inmeasuring
incremental effectiveness yields results that are consistentwith those based on the
existing reference standard. The argument is exemplified through the analysis of
EQ-5D in published studies.
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Graphical tests are very useful for assessing the fit of statistical models. In linear
regressionmodels, for instance, a plot of predicted means against observed values
can reveal systematic over- or under-prediction. Similar graphical tests are not
necessarily straightforward for other types of regression models like those based
on parametric survival distributions (e.g., to predict life-expectancy, time to pro-
gression of disease), particularly when multiple predictors are included in the
model. The first complicating issue is censoring, which makes a scatter plot of
individual observed and predicted values difficult to interpret. A better approach is
to plot the empirical distributions (i.e., Kaplan-Meier curves) derived from the ob-
served and predicted values, which inherently accounts for censoring in observed
times. The second andmore intricate issue is the definition of the predicted values.
In linear regression models, predictions represent the mean of the underlying
normal distribution that produced the observation. Since the normal distribution is
symmetric, it is reasonable to expect half of the observations to fall below their
means, and the rest to fall above. Parametric survival distributions are highly
skewed, however, so that the mean would generally be expected to exceed most
observed values. Similar problems arise if one uses the median (or any one partic-
ular percentile) as a reference, or plots the overall predicted curve at the mean
predicted value of the regression parameter (i.e., the scale of the distribution). An
accurate depiction of the overall predicted curve can be obtained instead by gen-
eratingmultiple randomevent times from each individual’s predicted distribution,
and using these to derive the overall predicted curve. The approach will be illus-
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